Last reviewed · How we verify
Nipolazin (MEQUITAZINE)
Nipolazin (generic name: MEQUITAZINE) is a mequitazine drug. It is currently in Phase 2 development.
Mequitazine works by blocking the action of acetylcholine at the muscarinic acetylcholine receptor M3.
Nipolazin, also known as mequitazine, is a small molecule drug that targets the muscarinic acetylcholine receptor M3. It belongs to the mequitazine class and works by blocking the action of acetylcholine at this receptor, which is involved in various physiological processes. Mequitazine is used to treat allergic conditions, but its exact indications and commercial status are unknown. As a result, its half-life, bioavailability, and generic manufacturers are also unclear. Further research is needed to determine its full potential and safety profile.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | MEQUITAZINE |
|---|---|
| Drug class | mequitazine |
| Target | Histamine H1 receptor, Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2 |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | Phase 2 |
Mechanism of action
Imagine your body has a system of messengers, called neurotransmitters, that help different parts work together. Acetylcholine is one of these messengers that helps control things like heart rate and breathing. Mequitazine blocks the action of acetylcholine at the M3 receptor, which can help reduce symptoms of allergic conditions.
Approved indications
Common side effects
- Tubulointerstitial nephritis and uveitis syndrome
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nipolazin CI brief — competitive landscape report
- Nipolazin updates RSS · CI watch RSS
Frequently asked questions about Nipolazin
What is Nipolazin?
How does Nipolazin work?
What is the generic name of Nipolazin?
What drug class is Nipolazin in?
What development phase is Nipolazin in?
What are the side effects of Nipolazin?
What does Nipolazin target?
Related
- Drug class: All mequitazine drugs
- Target: All drugs targeting Histamine H1 receptor, Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2
- Therapeutic area: All drugs in Neuroscience
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing